Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video
Video illustrates the potential of LB1148 to reduce the formation of adhesions in gastrointestinal (GI)…
News
VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo
Topline proof-of-concept data in vitiligo patients expected in 1H 2023 BRIDGEWATER, N.J., Nov. 17, 2022…
Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq:…
Science 37 and Linical Announce Partnership to Enable Fully Decentralized and Hybrid Trials
As a certified partner, Linical will leverage Science 37’s Metasite™ to provide global access to patients…
Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
BOTHELL, Wash., Nov. 17, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) today announced…
Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States
ZORYVE is now on formulary for one of the top pharmacy benefit managers serving commercially…
Rezo, Founded by Renowned UCSF Scientists, Launches with $78 Million Series A to Advance Pipeline of Precision Therapeutics Based on Groundbreaking Integrated Disease Network Mapping Platform
–Integration of technologies across proteomics, genetics, structural biology, chemistry, and bioinformatics enables advanced insights into…
TOWER ONE WIRELESS ANNOUNCES THIRTEEN TOWERS COMPLETED – ADDITIONAL NON-CANCELLABLE RENT OF $ 1,500,000
TOWER ONE CONSTRUCTION UPDATE FOR THE MONTH OF OCTOBER 2022 VANCOUVER, BC, CANADA , Nov….
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
Phase 1 results showed that AV-101 was generally well tolerated with significantly reduced systemic exposure…
Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of its US Phase 1/2 Clinical Trial for Type 1 Diabetes
Company’s recent recruitment strategy change has resulted in an unprecedented level of inquiries regarding potential…
InMed Provides Update on Management Changes
VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the…
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of consistent…
uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
~ Event to be Webcast Live on uniQure’s Corporate Website at 8:30 a.m. EST ~…
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
Survey finds primary care providers wish patients would raise mental health concerns so they can provide…
Gritstone to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage…
Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN),…
Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
-Broad partnership will strengthen Invivyd’s development platform and organizational capabilities towards acceleration of NVD200 clinical…
FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance a First-in-Class neuroprotectant
PRESS RELEASE FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV…
Immatics Announces Third Quarter 2022 Financial Results and Business Update
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective response…
CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
– Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX’s Probody® and…